Sébastien Salas

Summary

Country: France

Publications

  1. doi A study of 28 flat bone osteosarcomas: prognostic factors and early and long-term outcome
    S Salas
    Service d Oncologie Médicale Adulte, CHU Timone, APHM, 264 rue Saint Pierre, Marseille, France
    Eur J Cancer Care (Engl) 20:322-9. 2011
  2. pmc Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
    Florence Duffaud
    Centre Leon Berard, Department of Medecine, French Sarcoma Group GSF GETO, European Organisation for Research and Treatment of Cancer EORTC, University Claude Bernard Lyon I, Lyon, France
    Clin Sarcoma Res 2:11. 2012
  3. doi Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2
    Sébastien Salas
    Service Oncologie Medicale, Hopital de la Timone, Assistance Publique Hopitaux de Marseille, Marseille, France
    Int J Cancer 125:851-60. 2009
  4. doi Superficial soft tissue sarcomas (S-STS): a study of 367 patients from the French Sarcoma Group (FSG) database
    Sébastien Salas
    Department of Pathology, Bergonie Institute, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    Eur J Cancer 45:2091-102. 2009
  5. doi Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database
    S Salas
    Department of Pathology, Bergonie Institute, Bordeaux, France
    Ann Oncol 20:1127-35. 2009
  6. doi Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation
    Sébastien Salas
    Departement de Pathologie, Institut Bergonié 229, cours de l Argonne, Bordeaux, France CEDEX 33076
    J Clin Oncol 29:3553-8. 2011
  7. doi Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma
    Sébastien Salas
    Service d Oncologie Medicale, Adulte CHU Timone, APHM, Marseilles, France
    Radiother Oncol 87:195-200. 2008
  8. doi Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors
    Sébastien Salas
    Department of Pathology, INSERM U916, Bergonie Institute, 229 Cours de l Argonne, Bordeaux Cedex, France
    Genes Chromosomes Cancer 49:560-8. 2010
  9. ncbi Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas
    Sébastien Salas
    Service d Oncologie Médicale Adulte CHU Timone, APHM, Marseilles, France
    Virchows Arch 451:999-1007. 2007
  10. doi Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma
    Jean Laurent Deville
    INSERM, UMR 911 CRO2, Marseille, France
    Int J Cancer 125:2307-15. 2009

Detail Information

Publications19

  1. doi A study of 28 flat bone osteosarcomas: prognostic factors and early and long-term outcome
    S Salas
    Service d Oncologie Médicale Adulte, CHU Timone, APHM, 264 rue Saint Pierre, Marseille, France
    Eur J Cancer Care (Engl) 20:322-9. 2011
    ..Our results suggest a more favourable outcome of FBOS as the use of a treatment scheme based on the protocols for long bone osteosarcomas. However, an adequate local treatment is essential to ensure a better outcome...
  2. pmc Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
    Florence Duffaud
    Centre Leon Berard, Department of Medecine, French Sarcoma Group GSF GETO, European Organisation for Research and Treatment of Cancer EORTC, University Claude Bernard Lyon I, Lyon, France
    Clin Sarcoma Res 2:11. 2012
    ..ABSTRACT: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib : an active agent only in non progressive patients...
  3. doi Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2
    Sébastien Salas
    Service Oncologie Medicale, Hopital de la Timone, Assistance Publique Hopitaux de Marseille, Marseille, France
    Int J Cancer 125:851-60. 2009
    ..RPL8 and IFITM2 may be useful in the assessment at diagnosis and for stratifying patients taking part in randomized trials...
  4. doi Superficial soft tissue sarcomas (S-STS): a study of 367 patients from the French Sarcoma Group (FSG) database
    Sébastien Salas
    Department of Pathology, Bergonie Institute, 229 Cours de l Argonne, 33076 Bordeaux Cedex, France
    Eur J Cancer 45:2091-102. 2009
    ..We describe the clinical characteristics of a large series of S-STS (N=367) from the French Sarcoma Group (GSF-GETO) database and analyse the prognostic factors affecting outcome...
  5. doi Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database
    S Salas
    Department of Pathology, Bergonie Institute, Bordeaux, France
    Ann Oncol 20:1127-35. 2009
    ..Soft tissue sarcomas of the trunk wall (STS-TW) are usually studied together with soft tissue sarcomas of other locations. We report a study on STS-TW forming part of the French Sarcoma Group database...
  6. doi Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation
    Sébastien Salas
    Departement de Pathologie, Institut Bergonié 229, cours de l Argonne, Bordeaux, France CEDEX 33076
    J Clin Oncol 29:3553-8. 2011
    ..We present the results of the largest series of sporadic desmoid tumors ever published to determine the prognostic factors of these rare tumors...
  7. doi Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma
    Sébastien Salas
    Service d Oncologie Medicale, Adulte CHU Timone, APHM, Marseilles, France
    Radiother Oncol 87:195-200. 2008
    ..This study sought to evaluate nutritional prognostic factors before treatment in patients with unresectable head and neck cancer treated by concomitant radio-chemotherapy...
  8. doi Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors
    Sébastien Salas
    Department of Pathology, INSERM U916, Bergonie Institute, 229 Cours de l Argonne, Bordeaux Cedex, France
    Genes Chromosomes Cancer 49:560-8. 2010
    ..A better understanding of the pathogenetic pathways in the initiation and progression of desmoid tumors requires studies of 8q and 20q gains, as well as of 6q and 5q losses, and study of the Wnt/beta-catenin pathway...
  9. ncbi Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas
    Sébastien Salas
    Service d Oncologie Médicale Adulte CHU Timone, APHM, Marseilles, France
    Virchows Arch 451:999-1007. 2007
    ..001 and p = 0.003, respectively, and alpha-smooth muscle actin for OS only (p = 0.024). Our findings suggest that ezrin and alpha-smooth muscle actin are predictive IHC prognostic markers for patients with an osteosarcoma...
  10. doi Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma
    Jean Laurent Deville
    INSERM, UMR 911 CRO2, Marseille, France
    Int J Cancer 125:2307-15. 2009
    ..These findings highlight the implication of the AM pathway in the metastatic process and the prognostic relevance of AM in cRCC and point to a potential new therapeutic target...
  11. doi Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity
    Frederic Chibon
    Departement de Pathologie, Institut Bergonie, Bordeaux, France
    Nat Med 16:781-7. 2010
    ..Application of the signature will permit more selective use of adjuvant therapies for people with sarcomas, leading to decreased iatrogenic morbidity and improved outcomes for such individuals...
  12. ncbi Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma
    Geoffroy Venton
    Medical Oncology Unit, La Timone Hospital, 264 rue Saint Pierre, 13385 Marseilles Cedex 5, France
    Anticancer Res 32:701-5. 2012
    ..This case highlights potential synergy between sunitinib and radiation therapy in clear cell renal carcinoma...
  13. ncbi Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma
    Sébastien Salas
    Medical Oncology Unit, Clinical Pharmacokinetics Unit, La Timone University Hospital, Marseille, France
    Ther Drug Monit 28:532-9. 2006
    ..It is noteworthy that despite these markedly higher doses, little severe toxicity was reported, and all of the patients presented in this study were still alive and disease free after a follow-up of up to 15 years...
  14. doi Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: Prospective randomized trial
    Sébastien Salas
    Service d Oncologie Médicale Adulte, CHU Timone, APHM, Marseille, France
    Radiother Oncol 93:503-9. 2009
    ..The objectives of this study were to assess the impact of prophylactic gastrostomy on the 6-month quality of life, and to determine the factors related to this quality of life...
  15. doi Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma
    Sébastien Salas
    Service d Anatomie Pathologique, Hopital La Timone, Assistance Publique Hopitaux de Marseille, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France
    Virchows Arch 454:81-7. 2009
    ..Ezrin expression in chondroblastomas is more intriguing and requires further study to assess prognostic value...
  16. doi Adrenomedullin as a therapeutic target in angiogenesis
    Jean Laurent Deville
    INSERM UMR 911 CRO2, Faculte de Medecine Timone, 13385 Marseille Cedex 05, F 13000, France
    Expert Opin Ther Targets 14:1059-72. 2010
    ..AM is believed to play an important role in tumor progression and angiogenesis in many cancers. Therefore, it could become a new therapeutic target...
  17. ncbi Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters
    Francois Bertucci
    Département d Oncologie Moléculaire, Institut Paoli Calmettes and U119 Inserm, IFR57, Marseille, France
    Oncogene 23:1377-91. 2004
    ..These results suggest that microarrays may provide means to improve the classification of CRC, provide new potential targets against carcinogenesis and new diagnostic and/or prognostic markers and therapeutic targets...
  18. doi Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care
    Sébastien Salas
    Service d Oncologie Médicale Adulte et de Soins Palliatifs, CHU Timone, APHM, Universite de la Mediterranee, Marseille, France
    J Palliat Med 15:287-93. 2012
    ..The literature has described the use of ketamine as an adjuvant treatment for opioid-refractory cancer pain. None of these studies have used the drug in a palliative care patient population...
  19. ncbi [A study of the social representations in chemotherapy: a way to analyse the relations between patients and oncologists]
    Patrice Cannone
    Psychologue clinicien, Service d Oncologie Medicale, CHU Timone, 264 rue Saint Pierre, 13385 Marseille
    Bull Cancer 91:279-84. 2004
    ....